Literature DB >> 17016152

Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease.

Iacopo Cancelli1, Italo Pittaro Cadore, Giovanni Merlino, Luca Valentinis, Ugo Moratti, Paolo Bergonzi, Gian Luigi Gigli, Mariarosaria Valente.   

Abstract

Sensory gating is defined as the brain's ability to inhibit repetitive and irrelevant incoming sensory stimuli and is supposed to be related to cholinergic transmission. Indeed, Alzheimer's disease (AD) is characterized by a cholinergic deficit that is believed to be involved in cerebral cortex hyperexcitability and short latency afferent inhibition deficit. Therefore, a sensory gating deficit may be supposed present in AD within the frame of cortex hyperexcitability and loss of cortex modulation of sensory inputs. The authors investigated whether a sensory gating deficit may be present in AD and whether this deficit may be related to the presence of neuropsychiatric symptoms (NPS) and reversed by donepezil treatment. Sensory gating was evaluated using a paired-stimulus auditory P50 event-related potential paradigm. Eighteen drug-naïve probable AD patients (mean age 76.1 years; SD 5.6 years; 13 females and 5 males) and 15 healthy elderly controls (mean age 74.2 years; SD 5.4 years; 10 females and 5 males) were recruited. Sensory gating was evaluated in AD patients before starting therapy and after 1 and 3 months of donepezil treatment. Auditory P50 sensory gating was impaired in AD patients but no correlation was found between gating deficit and NPS. Moreover, AD patients displayed increased P50 amplitude when compared with healthy elderly subjects. Donepezil treatment did not improve P50 sensory gating in AD patients but decreased P50 amplitude. Patients with AD displayed an augmented P50 amplitude, in accordance with previous studies, suggesting increased cortex excitability. Donepezil does not affect P50 sensory gating but reduces P50 amplitude. Donepezil may induce P50 amplitude reduction by means of enhanced dopamine release. Indeed, it has been demonstrated that donepezil induces dopamine release "in vitro." The findings suggest that AD patients have a sensory gating impairment but the link with both NPS and the cholinergic deficit is doubtful.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016152     DOI: 10.1097/01.wnp.0000218991.99714.ee

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  13 in total

1.  Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.

Authors:  Inge Klinkenberg; Arjan Blokland; Wim J Riedel; Anke Sambeth
Journal:  Psychopharmacology (Berl)       Date:  2012-10-03       Impact factor: 4.530

Review 2.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

Review 3.  Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients.

Authors:  Iacopo Cancelli; Massimiliano Beltrame; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Neurol Sci       Date:  2009-02-20       Impact factor: 3.307

4.  Effects of glutamate receptor agonists on the p13 auditory evoked potential and startle response in the rat.

Authors:  Christen Simon; Tiffany Wallace-Huitt; Priyenka Thapa; Robert D Skinner; Edgar Garcia-Rill
Journal:  Front Neurol       Date:  2011-01-27       Impact factor: 4.003

5.  Modulatory role of the prefrontal generator within the auditory M50 network.

Authors:  Sanja Josef Golubic; Cheryl J Aine; Julia M Stephen; John C Adair; Janice E Knoefel; Selma Supek
Journal:  Neuroimage       Date:  2014-02-13       Impact factor: 6.556

6.  Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.

Authors:  Soumee Bhattacharya; Christin Haertel; Alfred Maelicke; Dirk Montag
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

7.  Neurophysiological Effects of Aging: A P200 ERP Study.

Authors:  Ali K Bourisly; Ali Shuaib
Journal:  Transl Neurosci       Date:  2018-06-22       Impact factor: 1.757

8.  The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.

Authors:  Guy Griebel; Jeanne Stemmelin; Mati Lopez-Grancha; Denis Boulay; Gerald Boquet; Franck Slowinski; Philippe Pichat; Sandra Beeské; Shinji Tanaka; Akiko Mori; Masatake Fujimura; Junichi Eguchi
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

9.  Dysfunction of Inferior Parietal Lobule During Sensory Gating in Patients With Amnestic Mild Cognitive Impairment.

Authors:  Chia-Hsiung Cheng; Fu-Jung Hsiao; Yu-Wei Hsieh; Pei-Ning Wang
Journal:  Front Aging Neurosci       Date:  2020-02-25       Impact factor: 5.750

10.  Effect of Mild Cognitive Impairment and Alzheimer Disease on Auditory Steady-State Responses.

Authors:  Elaheh Shahmiri; Zahra Jafari; Maryam Noroozian; Azadeh Zendehbad; Hassan Haddadzadeh Niri; Ali Yoonessi
Journal:  Basic Clin Neurosci       Date:  2017 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.